TDMS Study 05217-05 Pathology Tables
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
Facility: Southern Research Institute
Chemical CAS #: 1948-33-0
Lock Date: 08/04/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 9 8 9 6
Early Deaths
Moribund Sacrifice 11 7 6 6
Natural Death 2 10 5 5
Survivors
Terminal Sacrifice 37 35 40 42
Natural Death 1 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (58) (58) (56) (60)
Intestine Large, Cecum (60) (58) (57) (59)
Intestine Small, Duodenum (60) (59) (57) (59)
Leiomyosarcoma 1 (2%)
Intestine Small, Jejunum (60) (59) (57) (59)
Intestine Small, Ileum (60) (59) (56) (59)
Liver (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 7 (12%) 9 (15%) 7 (12%) 4 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 8 (13%) 11 (18%) 12 (20%) 4 (7%)
Hepatocellular Adenoma, Multiple 1 (2%) 9 (15%) 5 (8%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Mesentery (10) (13) (7) (9)
Hepatocellular Carcinoma, Metastatic, Liver 1 (14%)
Histiocytic Sarcoma 1 (14%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (8%)
Pancreas (60) (60) (58) (60)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Salivary Glands (60) (60) (60) (58)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (3%)
Stomach, Glandular (60) (60) (58) (60)
Page 2
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (59) (60)
Capsule, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Adrenal Medulla (60) (59) (60) (60)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (57) (60)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (58) (52) (55) (55)
Pars Distalis, Adenoma 5 (9%) 5 (10%) 5 (9%) 4 (7%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (60) (59) (59) (60)
Follicular Cell, Adenoma 1 (2%) 3 (5%) 2 (3%) 5 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (1)
Pelvic, Hemangiosarcoma, Multiple 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (60) (60) (59) (60)
Ovary (59) (57) (56) (56)
Cystadenoma 2 (3%) 2 (4%) 4 (7%) 2 (4%)
Granulosa Cell Tumor Malignant 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Luteoma 1 (2%)
Teratoma NOS 1 (2%)
Uterus (60) (60) (59) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (3%) 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Adenoma 1 (2%) 1 (2%)
Endometrium, Carcinoma 1 (2%)
Endometrium, Polyp Stromal 3 (5%) 1 (2%)
Page 3
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Lymph Node (7) (8) (12) (9)
Iliac, Histiocytic Sarcoma 1 (14%) 1 (8%)
Inguinal, Histiocytic Sarcoma 1 (13%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (8%)
Mediastinal, Histiocytic Sarcoma 1 (8%)
Renal, Histiocytic Sarcoma 1 (14%) 1 (8%)
Lymph Node, Mandibular (57) (60) (59) (57)
Lymph Node, Mesenteric (59) (56) (58) (56)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Spleen (60) (60) (59) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (53) (59) (56) (54)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (59) (60) (60)
Carcinoma 1 (2%)
Myoepithelioma 1 (2%)
Skin (60) (60) (60) (60)
Basal Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 2 (3%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (3%) 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1) (2)
Hepatocellular Carcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 3 (5%) 2 (3%) 4 (7%) 3 (5%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 1 (2%)
Basal Cell Carcinoma, Metastatic, Skin 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 4 (7%) 2 (3%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mediastinum, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (6) (1)
Adenoma 6 (100%) 1 (100%)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (59) (59)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Urinary Bladder (60) (59) (59) (59)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 2 (3%) 3 (5%) 4 (7%)
Lymphoma Malignant 3 (5%) 9 (15%) 10 (17%) 8 (13%)
Lymphoma Malignant Mixed 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 33 42 38 33
Total Primary Neoplasms 47 62 73 49
Total Animals with Benign Neoplasms 23 26 27 19
Total Benign Neoplasms 26 34 44 25
Total Animals with Malignant Neoplasms 18 23 22 22
Total Malignant Neoplasms 21 28 29 23
Total Animals with Metastatic Neoplasms 2 3 6 3
Total Metastatic Neoplasm 2 6 12 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 9 9
Early Deaths
Natural Death 4 1 6 2
Moribund Sacrifice 6 3 7 7
Accidently Killed 1
Survivors
Terminal Sacrifice 39 46 38 42
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (60) (60) (57) (59)
Carcinoma 1 (2%) 3 (5%)
Intestine Small, Ileum (59) (59) (58) (58)
Carcinoma 1 (2%)
Liver (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 2 (3%) 1 (2%)
Hepatocellular Carcinoma 5 (8%) 9 (15%) 8 (13%) 8 (13%)
Hepatocellular Carcinoma, Multiple 3 (5%) 2 (3%) 4 (7%) 1 (2%)
Hepatocellular Adenoma 22 (37%) 15 (25%) 18 (30%) 11 (18%)
Hepatocellular Adenoma, Multiple 7 (12%) 8 (13%) 5 (8%) 3 (5%)
Histiocytic Sarcoma 2 (3%)
Mesentery (2) (7) (15) (1)
Histiocytic Sarcoma 1 (14%) 2 (13%)
Pancreas (59) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (59) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (3%)
Stomach, Glandular (59) (60) (60) (59)
Carcinoid Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (59) (60)
Subcapsular, Adenoma 1 (2%) 4 (7%) 1 (2%) 2 (3%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 1 (2%) 1 (2%) 2 (3%)
Parathyroid Gland (59) (56) (58) (53)
Adenoma 1 (2%)
Pituitary Gland (55) (52) (53) (57)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (60) (60) (59) (60)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 2 (3%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (59)
Hemangioma 1 (2%)
Preputial Gland (60) (59) (59) (59)
Histiocytic Sarcoma 1 (2%)
Testes (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (3) (3) (6) (3)
Iliac, Histiocytic Sarcoma 2 (33%)
Inguinal, Histiocytic Sarcoma 1 (33%)
Mediastinal, Histiocytic Sarcoma 1 (33%) 1 (17%)
Pancreatic, Histiocytic Sarcoma 1 (17%)
Renal, Histiocytic Sarcoma 1 (33%) 1 (17%)
Lymph Node, Mandibular (58) (58) (58) (60)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (60) (58) (60) (60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 4 (7%) 1 (2%)
Page 8
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (53) (48) (52) (51)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (3%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (1) (1)
Hemangiosarcoma, Multiple 1 (50%)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (58) (60) (60)
Alveolar/Bronchiolar Adenoma 11 (18%) 9 (16%) 10 (17%) 10 (17%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 3 (5%) 2 (3%) 4 (7%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%) 1 (2%) 2 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (7%) 1 (2%) 2 (3%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
External Ear, Histiocytic Sarcoma 1 (100%)
Harderian Gland (3) (9) (6) (3)
Adenoma 2 (67%) 8 (89%) 4 (67%) 3 (100%)
Carcinoma 2 (33%)
Bilateral, Adenoma 1 (33%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 2 (3%) 1 (2%)
Lymphoma Malignant 4 (7%) 2 (3%) 6 (10%) 4 (7%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05217-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYLHYDROQUINONE Date: 04/04/96
Route: DOSED FEED Time: 08:56:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.125% 0.25% 0.5%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 46 45 39
Total Primary Neoplasms 79 74 73 59
Total Animals with Benign Neoplasms 34 39 34 27
Total Benign Neoplasms 51 50 43 35
Total Animals with Malignant Neoplasms 21 23 25 21
Total Malignant Neoplasms 28 24 30 24
Total Animals with Metastatic Neoplasms 5 1 2 1
Total Metastatic Neoplasm 5 1 2 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------